A Randomized, Phase III, Open-label Study of Lapatinib Plus Trastuzumab Versus Trastuzumab as Continued HER2 Suppression Therapy After Completion of First- or Second-line Trastuzumab Plus Chemotherapy in Subjects With HER2-positive Metastatic Breast Cancer.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Jun 2017
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 06 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 06 Jun 2017 Planned End Date changed from 1 Dec 2017 to 31 Dec 2019.
- 28 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2017.